The Dragon PLC Trial (DRAGON-PLC)

The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma. The main questions this trial aims to answer are whether combined PVE and HVE increases the proportion of patients who become resectable within 3 weeks and improves 5-year overall survival compared to PVE alone by enhanci

Trial Details

NCT ID
NCT06914648
Phase
NA
Sponsor
Maastricht University
Status
RECRUITING
Cancer Type
Cholangiocarcinoma (Bile Duct) Liver Cancer
Interventions
  • Portal Vein Embolization
  • Hepatic Vein Embolization
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • New York, New York, United States|40.71427,-74.00597
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • PLC diagnosis, specifically iCCC, pCCC, and HCC;
  • Requiring PVE due to an FLR volume is \<30% in normally functioning livers, \<40% in livers with potentially impaired function e.g. resulting from …
  • Age ≥ 18 years;
  • Able to understand the trial and provide informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cholangiocarcinoma (Bile Duct) Liver Cancer Trials on Trialify →